See more : Bangkok Life Assurance Public Company Limited (BLA.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Qrons Inc. (QRON) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Qrons Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Voestalpine AG (VLPNF) Income Statement Analysis – Financial Results
- Ossen Innovation Co., Ltd. (OSN) Income Statement Analysis – Financial Results
- Wolfden Resources Corporation (WLFFF) Income Statement Analysis – Financial Results
- Build Acquisition Corp. (BGSX-UN) Income Statement Analysis – Financial Results
- AOTI, Inc. (AOTI.L) Income Statement Analysis – Financial Results
Qrons Inc. (QRON)
About Qrons Inc.
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 462.46K | 194.41K | 258.30K | 258.62K | 651.48K | 919.71K | 1.18M | 156.00K |
| General & Administrative | 181.22K | 435.22K | 543.66K | 295.12K | 864.96K | 2.99M | 223.37K | 20.32K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.48K | -10.95K |
| SG&A | 181.22K | 435.22K | 543.66K | 295.12K | 864.96K | 2.99M | 223.37K | 9.37K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 643.68K | 629.63K | 801.95K | 553.74K | 1.52M | 3.90M | 1.40M | 165.37K |
| Cost & Expenses | 643.68K | 629.63K | 801.95K | 553.74K | 1.52M | 3.90M | 1.40M | 165.37K |
| Interest Income | 0.00 | 135.65 | 208.89 | 52.02 | 42.57 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.59K | 135.65K | 208.89K | 52.02K | 42.57K | 20.35K | 14.21K | 3.87K |
| Depreciation & Amortization | 643.68K | 629.63K | 801.95K | 553.74K | 1.52M | 3.90M | 1.40M | 488.32K |
| EBITDA | -40.08K | -629.63K | -801.95K | -553.74K | -1.52M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -643.68K | -629.63K | -801.95K | -553.74K | -1.52M | -3.90M | -1.40M | -165.37K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -145.67K | -103.89K | -266.03K | -109.22K | -30.34K | -26.08K | -20.30K | 326.87K |
| Income Before Tax | -789.35K | -733.52K | -1.07M | -662.96K | -1.55M | -3.93M | -1.42M | -169.24K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -31.77K | 208.89K | 52.02K | 42.57K | 26.08K | -1.39M | -488.32K |
| Net Income | -789.35K | -701.75K | -1.28M | -714.98K | -1.59M | -3.93M | -1.42M | -169.24K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.05 | -0.10 | -0.05 | -0.12 | -0.31 | -0.12 | -0.01 |
| EPS Diluted | -0.06 | -0.05 | -0.10 | -0.05 | -0.12 | -0.31 | -0.12 | -0.01 |
| Weighted Avg Shares Out | 13.53M | 13.30M | 13.29M | 13.16M | 13.00M | 12.77M | 11.66M | 11.54M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.30M | 13.29M | 13.16M | 13.00M | 12.77M | 11.66M | 11.54M |
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries
Source: https://incomestatements.info
Category: Stock Reports